Dr. Nandini Menon: Biomarkers for Predicting Immunotherapy Efficacy (Non-PD-L1/MSI/TMB) | CRSF

Welcome to the CRSF 7th Masterclass in Lung Cancer, held on 19th July 2024. In this session, Dr. Nandini Menon from Mumbai presents on Biomarkers for Predicting Efficacy of Immunotherapy in cases where traditional biomarkers like PD-L1, MSI, and TMB are not applicable.

Dr. Menon explores alternative biomarkers and approaches for evaluating the effectiveness of immunotherapy in lung cancer patients who do not have PD-L1 expression, MSI, or high TMB. This session focuses on how to identify and use these biomarkers to guide treatment decisions and improve patient outcomes.

Key topics include:

Overview of Immunotherapy: Brief review of immunotherapy and its reliance on traditional biomarkers such as PD-L1, MSI, and TMB.
Alternative Biomarkers: Identification of novel and emerging biomarkers that can be used to predict immunotherapy efficacy when PD-L1, MSI, and TMB are not present.
Clinical Applications: How these alternative biomarkers are applied in clinical practice to guide treatment strategies and monitor patient responses.
Research and Evidence: Review of recent studies and trials investigating the role of non-traditional biomarkers in immunotherapy.
Case Studies and Practical Insights: Real-world examples and insights into managing patients using alternative biomarkers to optimize treatment outcomes.
Dr. Menon emphasizes the need for a comprehensive approach to biomarker evaluation, highlighting the potential for improved patient selection and treatment strategies in immunotherapy. This session is valuable for oncologists, researchers, and healthcare professionals seeking to enhance their understanding of biomarker-based treatment approaches.

#CRSF #LungCancerMasterclass #Immunotherapy #Biomarkers #NonPDL1 #NonMSI #NonTMB #DrNandiniMenon #CancerTreatment #Oncology #CRSFMasterclass2024